VIDEO: Decitabine plus ipilimumab shows ‘promising clinical activity’ in AML
Click Here to Manage Email Alerts
In patients with relapsed or refractory or secondary acute myeloid leukemia/myelodysplastic syndromes, decitabine plus ipilimumab had an expected adverse event profile and showed encouraging clinical activity, according to an ongoing phase 1 study.
Jacqueline S. Garcia, MD, of the department of medical oncology at Dana-Farber Cancer Institute, presented the data at the ASH Annual Meeting and Exposition.
“What’s notable is for the post-transplant patients, the median overall survival was about 7.5 months, but for the transplant naive patients the median overall survival was about 18.3 months, that was really reassuring,” Garcia said. “We saw some promising clinical activity. This is not a randomized study, but we do see a decent objective response suggesting that the combination could be active.”
Collapse
Garcia JS, et al. Abstract 170. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts